11.13.13
United Kingdom-based medical device manufacturer Smiths Medical has initiated the first phase of a new production unit in the Prerov region of the Czech Republic.
The company moved into the 29,500-square-foot manufacturing and assembly facility at the CTPark industrial zone in Hranice in July 2013 and the leased unit officially was opened in September.
Smiths Medical will turn out a range of high-tech products at the plant, primarily single-use medical devices to support breathing and for drug delivery. The facility includes state-of-the-art clean room facilities.
The firm, a division of London, England-based global technology group Smiths Group, is investing more than approximately $9 billion on the Czech plant, which is set to employ up to 300. It will be fully operational in the first half of 2014.
Smiths Medical produces a range of high-tech devices used for surgical procedures and hospital care, including equipment for cardiovascular treatment, incubation and in-vitro fertilization.
The company, which had headline revenue of almost $1.3 billion in fiscal 2013, has other European production plants in Germany, Italy and the U.K., with production units in China, Mexico and the United States. The company employs 7,900 worldwide.
The company moved into the 29,500-square-foot manufacturing and assembly facility at the CTPark industrial zone in Hranice in July 2013 and the leased unit officially was opened in September.
Smiths Medical will turn out a range of high-tech products at the plant, primarily single-use medical devices to support breathing and for drug delivery. The facility includes state-of-the-art clean room facilities.
The firm, a division of London, England-based global technology group Smiths Group, is investing more than approximately $9 billion on the Czech plant, which is set to employ up to 300. It will be fully operational in the first half of 2014.
Smiths Medical produces a range of high-tech devices used for surgical procedures and hospital care, including equipment for cardiovascular treatment, incubation and in-vitro fertilization.
The company, which had headline revenue of almost $1.3 billion in fiscal 2013, has other European production plants in Germany, Italy and the U.K., with production units in China, Mexico and the United States. The company employs 7,900 worldwide.